Molecular Mechanisms of Synaptic Dysregulation in Fragile X Syndrome and Autism Spectrum Disorders
- PMID: 30899214
- PMCID: PMC6417395
- DOI: 10.3389/fnmol.2019.00051
Molecular Mechanisms of Synaptic Dysregulation in Fragile X Syndrome and Autism Spectrum Disorders
Abstract
Fragile X syndrome (FXS) is the most common form of monogenic hereditary cognitive impairment. FXS patient exhibit a high comorbidity rate with autism spectrum disorders (ASDs). This makes FXS a model disease for understanding how synaptic dysregulation alters neuronal excitability, learning and memory, social behavior, and more. Since 1991, with the discovery of fragile X mental retardation 1 (FMR1) as the sole gene that is mutated in FXS, thousands of studies into the function of the gene and its encoded protein FMR1 protein (FMRP), have been conducted, yielding important information regarding the pathophysiology of the disease, as well as insight into basic synaptic mechanisms that control neuronal networking and circuitry. Among the most important, are molecular mechanisms directly involved in plasticity, including glutamate and γ-aminobutyric acid (GABA) receptors, which can control synaptic transmission and signal transduction, including short- and long-term plasticity. More recently, several novel mechanisms involving growth factors, enzymatic cascades and transcription factors (TFs), have been proposed to have the potential of explaining some of the synaptic dysregulation in FXS. In this review article, I summarize the main mechanisms proposed to underlie synaptic disruption in FXS and ASDs. I focus on studies conducted on the Fmr1 knock-out (KO) mouse model and on FXS-human pluripotent stem cells (hPSCs), emphasizing the differences and even contradictions between mouse and human, whenever possible. As FXS and ASDs are both neurodevelopmental disorders that follow a specific time-course of disease progression, I highlight those studies focusing on the differential developmental regulation of synaptic abnormalities in these diseases.
Keywords: autism spectrum disorders; fragile X syndrome; human embryonic stem cells; human induced pluripotent stem cells; human pluripotent stem cells; mouse models; synaptic plasticity.
Similar articles
-
BDNF in fragile X syndrome.Neuropharmacology. 2014 Jan;76 Pt C:729-36. doi: 10.1016/j.neuropharm.2013.05.018. Epub 2013 May 29. Neuropharmacology. 2014. PMID: 23727436 Review.
-
Inhibition of GluN2A NMDA receptors ameliorates synaptic plasticity deficits in the Fmr1-/y mouse model.J Physiol. 2018 Oct;596(20):5017-5031. doi: 10.1113/JP276304. Epub 2018 Sep 19. J Physiol. 2018. PMID: 30132892 Free PMC article.
-
microRNAs and Fragile X Syndrome.Adv Exp Med Biol. 2015;888:107-21. doi: 10.1007/978-3-319-22671-2_7. Adv Exp Med Biol. 2015. PMID: 26663181
-
Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.Pediatr Neurol. 2014 Apr;50(4):297-302. doi: 10.1016/j.pediatrneurol.2013.12.001. Epub 2013 Dec 4. Pediatr Neurol. 2014. PMID: 24518745 Review.
-
Synaptic vesicle dynamic changes in a model of fragile X.Mol Autism. 2016 Mar 1;7:17. doi: 10.1186/s13229-016-0080-1. eCollection 2016. Mol Autism. 2016. PMID: 26933487 Free PMC article.
Cited by
-
mGluR5 Negative Modulators for Fragile X: Treatment Resistance and Persistence.Front Psychiatry. 2021 Sep 29;12:718953. doi: 10.3389/fpsyt.2021.718953. eCollection 2021. Front Psychiatry. 2021. PMID: 34658956 Free PMC article.
-
Spatially coordinated heterochromatinization of long synaptic genes in fragile X syndrome.Cell. 2023 Dec 21;186(26):5840-5858.e36. doi: 10.1016/j.cell.2023.11.019. Cell. 2023. PMID: 38134876 Free PMC article.
-
Astroglial FMRP deficiency cell-autonomously up-regulates miR-128 and disrupts developmental astroglial mGluR5 signaling.Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):25092-25103. doi: 10.1073/pnas.2014080117. Epub 2020 Sep 21. Proc Natl Acad Sci U S A. 2020. PMID: 32958647 Free PMC article.
-
Deletion of the Autism-Associated Protein SHANK3 Abolishes Structural Synaptic Plasticity after Brain Trauma.Int J Mol Sci. 2022 May 29;23(11):6081. doi: 10.3390/ijms23116081. Int J Mol Sci. 2022. PMID: 35682760 Free PMC article.
-
Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study.Brain Sci. 2022 Feb 26;12(3):314. doi: 10.3390/brainsci12030314. Brain Sci. 2022. PMID: 35326270 Free PMC article.
References
-
- Antar L. N., Afroz R., Dictenberg J. B., Carroll R. C., Bassell G. J. (2004). Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J. Neurosci. 24, 2648–2655. 10.1523/JNEUROSCI.0099-04.2004 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials